Search
for
Sort by
Research 121–150 of 530
- AP-2α/AP-2β transcription factors are key regulators of epidermal homeostasis
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- 1325 Age-dependent loss of the stemness and antimicrobial defense function of dermal fibroblasts is mediated by TGFbeta
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- JAK inhibitors in dermatology: The promise of a new drug class
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
- Current and future pharmacotherapy for alopecia areata
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Fibroblast heterogeneity and functions: insights from single-cell sequencing in wound healing, breast cancer, ovarian cancer and melanoma
- Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity
- Increase in IL-15 levels in patients with alopecia areata
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- LB1048 Effectiveness of OR-101 in a murine model of atopic dermatitis
- Review of Promising Off-Label Use of Deucravacitinib
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- Effects of Natural Herbal Marker Compounds on Human Dermal Papilla Cell Growth Regulation
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Alopecia areata: medical treatments
- Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
- Immune therapies for alopecia areata: evidence and new perspectives
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study